Chugai Pharmaceutical Co.

From Wikipedia, the free encyclopedia
  (Redirected from Chugai Pharmaceuticals)
Jump to navigation Jump to search

Chugai Pharmaceutical, 中外
Public (K.K)
Traded asTYO: 4519
IndustryPharmaceutical Industry, Business import, production and development of drugs for medical sales
Founded1943 March 8
HeadquartersNihonbashi Mitsui Tower, Nihonbashi Muromachi 2-1-1, Chūō, Tokyo
On the registration Headquarter: Tokyo Kita (Tokyo)
Key people
Osamu Nagayama - Chairman and Tatsuro Kosaka - CEO
Revenue72.9 billion capital of 47 million yen. Standalone sales of 329.2 billion yen and 344.8 billion yen consolidated
(December 2007)
Websitewww.chugai-pharm.co.jp (in Japanese)

Chugai Pharmaceutical Co., Ltd. (中外製薬株式会社, Chūgai Seiyaku Kabushikigaisha) is a drug manufacturer operating in Japan. It is a subsidiary controlled by Hoffmann–La Roche, which owns 62% of the company as of 30 June 2014.[1] The company is headquartered in Tokyo. Osamu Nagayama is the current representative director and chairman. Tatsuro Kosaka is the current representative director, president and CEO.

History[edit]

Other notable developments[edit]

Scientists at Chugai discovered an erythromycin-derived motilin agonist called mitemcinal (GM-611 or 3′-N-dimethyl-11-deoxy-3′-N-isopropyl-12-O-methyl-11-oxo-8,9-didehydroerythromycin). Mitemcinal was believed to have strong prokinetic properties, like its parent molecule, but lack antibiotic properties. Presently, erythromycin is commonly used off-label for gastric motility indications such as gastroparesis. If mitemcinal can be shown to be as effective a prokinetic agent, it would represent an advance in the field as treatment with this drug would not carry the risk of unintentional selection of antibiotic-resistant bacteria.

See also[edit]

References[edit]

  1. ^ Cortez, Michelle Fay; Matsuyama, Kanoko (25 August 2014). "Roche Said to Have Decided Against Bid for Rest of Chugai". Bloomberg.
  2. ^ Staff (2 March 2015). "Chugai to Co-Develop Athersys' Cell Therapy in Japan in Up-to-$205M Partnership". Genetic Engineering & Biotechnology News (Paper, Vol 35, i 7, p. 12). Retrieved 2016-06-11.

External links[edit]